Since parathyroid carcinomas are so uncommonly observed in the clinical settings as opposed to parathyroid adenomas, parafibromin immunohistochemistry will require almost near-perfect specificity to reduce the number of false positive cases. The gene discussed is CDC73; the disease is parathyroid gland carcinoma.